DRIVE-MRT

Home . Service . DRIVE-IDDS: integrated drug discovery solution . DRIVE-MRT

DRug Integrative discoVEry of Molecular RadioTherapy: A premium “nuclear medicine” solution in Oncology

DRIVE-MRT is part of our continuous improvement in the integrated drug discovery support. Oncodesign and its strategic partners Covalab, CheMatech, and ABX-CRO are applying their expertise in the rationalization, design, and optimization of targeted radiopharmaceutical agents.

We can support your preclinical proof of concept, dosimetry, and the clinical development in specific cancers.

This offer gives access to a comprehensive continuum of technological platforms together with our strategic partners’ complementary expertise.

The ABX-CRO, CheMatech, Covalab and Oncodesign joint value proposition for a DRIVE-MRT offer encompassing from hit finding, lead optimization to the preclinical candidate drug generation, IND and clinical development of radiopharmaceuticals can be built and strengthened upon the complementary technologies and expertise of all parties.

Contact DRIVE-MRT experts

All the steps for your radiopharmaceutical projects

premium services in molecular radiotherapy

Radiopharmaceutical development requires specific and dedicated expertise whatever the step you are at!

I schedule a discovery appointment

Hit finding and validation
What is the most specific vector for a Molecular RadioTherapy between full antibody and small fragments?
What is the best strategy to identify and select these various biological vectors?
We guide you in selecting the best high affinity antibody or fragments to be used for labeling & in vivo imaging
Lead optimization of bioconjugated candidates
Do you have a process to bioconjugate and radiolabel your compound? 
When linked with a chelating agent, do the compound have the same affinity, target engagement, in vivo biodistribution?
The key objective of the Lead optimization phase is to define the best strategy of bioconjugation, selection of linker (PEG, BSA binder…), and radiolabeling in order to select an optimal bioconjugated compound (and possibly 2-3 back-up compounds) with improved binding demonstrating a robust selectivity and in vivo biodistribution.
Preclinical proof of concept
To undergo regulatory IND-enabling studies, critical questions require to be addressed. What is the proof of concept and the pharmaceutical developability behind new target or biomarker? What is the therapeutic preclinical efficacy of this new molecule?

We design and implement preclinical studies to demonstrate the translational validity of novel pharmaceuticals as imaging or therapeutic agents using in vitro, ex vivo and in vivo assays in the appropriate models.
Preclinical Regulatory
How to define the regulatory preclinical package for a radiopharmaceutical for diagnostic or therapeutic application? 
We can provide you with a cGMP service to produce starting materials and intermediates. CheMatech conducts in-house cGMP manufacturing of chelating agents from grams to kilo. ABX-CRO will support your Radiopharmaceutical Development and dosimetry. Oncodesign can manage the toxicity studies and perform the GLP bioanalysis.
Clinical Development
What are the essentials for a successful preclinical strategy and applications for conducting radiopharmaceutical clinical trials?
- Close relationship between preclinical and clinical project managers to ensure continuity of your project
- Integrated protocol development campaigns with joint Key Opinion Leader panels from target (e.g. oncology,) and technical (nuclear medicine, radiology) medical fields
- Extensive project de-risking using advanced literature-based sample size estimations, and risk factor simulations
- Pharmacovigilance: Patient safety is critical and we understand the specific safety requirements associated with the use of radionuclides and imaging technologies.